ArticleFrontiers in medicine2025
A dual-model AI framework for Alzheimer's disease diagnosis using clinical and MRI data.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An interpretable multimodal ensemble assessment framework for Alzheimer's disease cognitive staging.Frontiers in neurology · 2026Article
- Capturing fine-grained spatial details in brain tumor MRI via multi-module feature enhancement.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder that requires advanced diagnostic strategies for early and accurate detection. Methods: This study introduces a hybrid AI-driven diagnostic framework that integrates an Artificial Neural Network (ANN) trained on clinical data from 1,200 patients using 31 demographic, symptomatic, and behavioral features with a Convolutional Neural Network (CNN) trained on 4,876 MRI images to classify AD into four stages. Results and Discussion: The ANN achieved an accuracy of 87.08% in early-stage risk prediction, while the CNN demonstrated a superior 97% accuracy in disease staging, supported by Grad-CAM visualizations that improved model interpretability. This dual-model approach effectively combines structured clinical data with imaging-based analysis, addressing the sensitivity and scalability limitations of traditional diagnostic methods and providing a more comprehensive assessment of AD. Conclusion: The integration of ANN and CNN enhances diagnostic precision and supports AI-assisted clinical decision-making, with future work focusing on lightweight CNN architectures and wearable technologies to enable broader accessibility and earlier intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.